Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $9.53 | N/A | +34.04% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $9.53 | N/A | +34.04% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management expressed confidence in the company's performance, highlighting the strong EPS results. They emphasized their commitment to innovation and growth.
We are pleased with our strong EPS performance this quarter.
Our focus remains on delivering innovative therapies.
Regeneron's strong EPS performance indicates effective cost management and potential for future profitability. The stock's slight increase reflects investor approval of the earnings results, despite the lack of revenue data or guidance. Overall, the company appears to be on a solid path, but investors will be looking for more comprehensive financial details in future reports.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMGEN INC
Feb 2, 2021